CONTENTS
ACKNOWLEDGEMENTS...................................................................................................I
1 INTRODUCTION...............................................................................................................................................1
Aim...........................................................................................................................................................................2
Cost-Effectiveness Analysis (CEA)..................................................................................................................2
Coronary Heart Disease (CHD).........................................................................................................................3
TheSWSAHS..........................................................................................................................................................4
Risk Factors..........................................................................................................................................................4
Risk Factors Used in this Analysis...................................................................................................................5
2 PREVIOUS CEAS ON NUTRITION INTERVENTIONS.............................................................................6
Weinstein and Stason (1985)...............................................................................................................................6
Kritiansen, Eggen and Thelle (1991)................................................................................................................8
Crowley, Dunt and Day (1995)..........................................................................................................................9
Hall et al (1988).................................................................................................................................................11
The Interventions in More Detail...................................................................................................................16
Some Key Issues for Each Intervention.................................................................................... 19
3 THE INTERVENTIONS.................................................................................................14
Theinterventiongroups..........................................................................................14
THE INTERVENTIONS IN MORE DETAILS...........................................................................16
4 COST-EFFECTIVENESS ANALYSIS...........................................................................................................21
Effectiveness......................................................................................................................................................21
Cost-effectiveness.............................................................................................................................................29
Sensitivity Analysis - Length of effectiveness...........................................................................................30
Sensitivity Analysis - Take-up rates of programs......................................................................................31
TAKE-UP RATE AMONGST GPS)...............................................................................................................................33
Summary of results...........................................................................................................................................33
5 DISCUSSION...................................................................................................................................................34
Healthy Public Policy......................................................................................................................................34
Building Partnerships.......................................................................................................................................35
Effectiveness and evidence: biomedical, clinical & social behaviour considerations.......................35
Behaviour modification....................................................................................................................................38
Portfolio Investment........................................................................................................................................40
Otherdiseases....................................................................................................................................................41
Equity...................................................................................................................................................................41
REFERENCES.....................................................................................................................................................43
Appendixa.......................................................................................................................................................54
Appendixb.......................................................................................................................................................55
Appendixc.......................................................................................................................................................65
More intriguing information
1. The name is absent2. ADJUSTMENT TO GLOBALISATION: A STUDY OF THE FOOTWEAR INDUSTRY IN EUROPE
3. The name is absent
4. Globalization, Divergence and Stagnation
5. Gender stereotyping and wage discrimination among Italian graduates
6. Program Semantics and Classical Logic
7. Social Irresponsibility in Management
8. On the Desirability of Taxing Charitable Contributions
9. The name is absent
10. The name is absent